6 January
2025
Graft Polymer (UK) Plc
("Graft Polymer" or the "Company")
Result of General Meeting and
change of name
The board of Graft Polymer
(LON:GPL), an innovative biotechnology company co-developing
therapeutics for mental health disorders, is pleased to announce
that the resolution proposed, to enable the Company to change its
name, was duly passed on a show of hands at the general meeting
(the "GM") held earlier today. The results of the proxy votes
received ahead of the meeting are set out below.
|
Resolution
|
Votes for*
|
%
|
Votes against
|
%
|
Votes total
|
Votes withheld**
|
|
Resolution 1
|
754,271,622
|
99.53
|
3,565,847
|
0.47%
|
757,837,469
|
0
|
* Includes discretionary
votes
**A vote withheld is not a vote in law and is not counted in
the calculation of the proportion of votes "For" or "Against" any
of the resolutions
Change of name
Having received shareholder approval
at the GM, the Company's name will be changed to Solvonis
Therapeutics plc. The relevant paperwork will be filed with
Companies House shortly, and a further announcement will be made
when the name change is formally effective. Upon the change of name
becoming effective, the Company's TIDM will change from "GPL" to
"SVNS".
The ISIN and SEDOL numbers for the
Company's ordinary shares will remain unchanged as GB00BMD1Z199 and
BMD1Z19 respectively.
Shareholders are unaffected by the
changes and existing share certificates will remain valid and
should be retained.
For more information, please
visit www.graftpolymer.co.uk.
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk
Allenby Capital (Financial Adviser and Broker)
+44 (0) 20 3328 5656
Nick Naylor / Liz Kirchner
(Corporate Finance) | Guy McDougall (Sales)
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc is an
innovative biotechnology company focused on developing intellectual property relating to the treatment of
mental health and substance use disorders, and the co-development
of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on
trauma-related mental health disorders, such as PTSD, which affects
approximately 13 million adults in the U.S. and 20 million in US,
UK, and key EU markets.